KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Net Cash Flow (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Net Cash Flow for 17 consecutive years, with -$30.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 145.78% to -$30.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$472.9 million, a 720.6% decrease, with the full-year FY2025 number at -$472.9 million, down 720.6% from a year prior.
  • Net Cash Flow was -$30.9 million for Q4 2025 at Bio-Rad Laboratories, up from -$95.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $324.7 million in Q1 2022 to a low of -$391.9 million in Q4 2021.
  • A 5-year average of -$49.1 million and a median of -$56.5 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 439.33% in 2022, then plummeted 902.52% in 2025.
  • Bio-Rad Laboratories' Net Cash Flow stood at -$391.9 million in 2021, then skyrocketed by 83.28% to -$65.5 million in 2022, then grew by 27.71% to -$47.4 million in 2023, then surged by 242.47% to $67.5 million in 2024, then crashed by 145.78% to -$30.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Net Cash Flow are -$30.9 million (Q4 2025), -$95.5 million (Q3 2025), and -$251.7 million (Q2 2025).